Health programs crave for diagnostic imaging and eradication of chemoresistant neoplastic lesions smaller than 1 mm of size.
PHIRE aims at bringing closer to market a novel high-resolution theranostic medical device effective in the clinical applications for lesions <1 mm, ready for application in human bladder cancer and effective both in male and female patients.
The Consortium is composed by hospital, academia and industrial researches located in Italy (San Raffaele Hospital and University of Bologna), United Kingdom (Ascend Technologies LTD), The Netherlands (Fujifilm Visualsonics) and Belgium (META Group).
Funding by the Horizon Europe programme, under GA No. 101113193
Company Details
- Founded
- -
- Address
- Ospedale San Raffaele, Via Olgettina 60, Milano,lombardia,italy
- Industry
- Nanotechnology Research
- NAICS
-
Research and Development in Nanotechnology
- Website
- https://www.phire-project.eu/
- Keywords
- bladder cancer, diagnostic imaging, artificial intelligence, nano-materials, health, theranostic, research project.
- HQ
- Milano, Lombardia
Phire Questions
Phire's website is https://www.phire-project.eu/
Phire's LinkedIn profile is https://it.linkedin.com/company/phireproject
Phire's industry is
Nanotechnology Research
Phire's top competitors are
Meta Group,
Vitalyv International,
Vediamocichiara - La Salute Dalla Parte Di Noi Donne,
Progetto Di Ricerca Start,
Storka Ab,
Siemens Healthineers,
Strong-Ur,
Chiaramonti S.r.l.,
Innovitas Vitae,
Abbott.
Phire's categories are Nanotechnology Research
Phire's founding year is 2023
